|
Celgene (CELG): Bet on biotech for 'offense and defense' |
|
| Oct 27, 2009 04:20 PM UTC |
|
|
Tracked Blogger
|
Via BloggingStocks:
Filed under: Newsletters, Stocks to Buy "I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reviews the leading biotechnology company. Wyatt explains, "Celgene engages in the discovery of therapies designed to treat cancer and immune inflammatory related diseases. They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA. "Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoiding the political and ethical questions dogging others involved in stem cell research. Continue reading Celgene (CELG): Bet on biotech for 'offense and defense' Celgene (CELG): Bet on biotech for 'offense and defense' originally appeared on BloggingStocks on Tue, 27 Oct 2009 11:20:00 EST. Please see our terms for use of feeds. Permalink | Email this | Comments
Read the rest of original post »
|
Be the first to comment on this story and earn 2 points.
|
|
IN THE PRESS |
|
|
|
|
|
|
| About | RSS | Feedback | Contact Us | Terms of Service | Privacy |
© 2009 FinancialContent Services, Inc. |
|
Data powered by FinancialContent. All Rights Reserved. Quotes delayed at least 20 minutes unless otherwise indicated. |
|
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. |
